Pharmaceutical

MAS-825 by Novartis for Coronary Artery Disease (CAD) (Ischemic Heart Disease): Likelihood of Approval

MAS-825 is under clinical development by Novartis and currently in Phase II for Coronary Artery Disease (CAD) (Ischemic Heart Disease).

Jun 18, 2024 - 04:00
MAS-825 is under clinical development by Novartis and currently in Phase II for Coronary Artery Disease (CAD) (Ischemic Heart Disease).
Read the original article

Tags:

Previous Article

Olanzapine ER by Teva Pharmaceutical Industries for Schizophrenia: Likelihood of...

Next Article

OCT-461201 by Oxford Cannabinoid Technologies for Visceral Pain: Likelihood of A...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Sanofi becomes the third leading insulin maker to lower list prices, cutting Lantus price by 78%

STAT+: Sanofi becomes the third leading insulin maker t...

Mar 19, 2023

STAT+: What the Covid-19 pandemic can teach us about drug patents

STAT+: What the Covid-19 pandemic can teach us about dr...

May 3, 2023

Novartis signs deal for Arvinas’ prostate cancer therapy

Novartis signs deal for Arvinas’ prostate cancer therapy

Apr 13, 2024